Hubbry Logo
GPERGPERMain
Open search
GPER
Community hub
GPER
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
GPER
GPER
GPER
View on Wikipedia
from Wikipedia

GPER1
Identifiers
AliasesGPER1, Gper1, 6330420K13Rik, CMKRL2, Ceprl, FEG-1, GPCR-Br, Gper, Gpr30, CEPR, DRY12, LERGU, LERGU2, LyGPR, mER, G protein-coupled estrogen receptor 1
External IDsOMIM: 601805; MGI: 1924104; HomoloGene: 15855; GeneCards: GPER1; OMA:GPER1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

2852

76854

Ensembl

ENSG00000164850

ENSMUSG00000053647

UniProt

Q99527

Q8BMP4

RefSeq (mRNA)

NM_001031682
NM_001039966
NM_001098201
NM_001505

NM_029771

RefSeq (protein)

NP_001035055
NP_001091671
NP_001496

NP_084047

Location (UCSC)Chr 7: 1.08 – 1.09 MbChr 5: 139.41 – 139.41 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

G protein-coupled estrogen receptor 1 (GPER), also known as G protein-coupled receptor 30 (GPR30), is a protein that in humans is encoded by the GPER gene.[5] GPER binds to and is activated by the female sex hormone estradiol and is responsible for some of the rapid effects that estradiol has on cells.[6]

Discovery

[edit]

The classical estrogen receptors first characterized in 1958[7] are water-soluble proteins located in the interior of cells that are activated by estrogenenic hormones such as estradiol and several of its metabolites such as estrone or estriol. These proteins belong to the nuclear hormone receptor class of transcription factors that regulate gene transcription. Since it takes time for genes to be transcribed into RNA and translated into protein, the effects of estrogens binding to these classical estrogen receptors is delayed. However, estrogens are also known to have effects that are too fast to be caused by regulation of gene transcription.[8] In 2005, it was discovered that a member of the G protein-coupled receptor (GPCR) family, GPR30 also binds with high affinity to estradiol and is responsible in part for the rapid non-genomic actions of estradiol. Based on its ability to bind estradiol, GPR30 was renamed as G protein-coupled estrogen receptor (GPER). GPER is localized in the plasma membrane but is predominantly detected in the endoplasmic reticulum.[9][8]

Ligands

[edit]

GPER binds estradiol with high affinity though not other endogenous estrogens, such as estrone or estriol, nor other endogenous steroids, including progesterone, testosterone, and cortisol.[6][9][10][11][12] Although potentially involved in signaling by aldosterone, GPER does not show any detectable binding towards aldosterone.[6][13][14] Niacin and nicotinamide bind to the receptor in vitro with very low affinity.[15][16] CCL18 has been identified as an endogenous antagonist of the GPER.[17] GPER-selective ligands (that do not bind the classical estrogen receptors) include the agonist G-1[18] and the antagonists G15[19] and G36.[20][6]

Agonists

[edit]

Antagonists

[edit]

Unknown

[edit]

Non-ligand

[edit]

Function

[edit]

This protein is a member of the rhodopsin-like family of G protein-coupled receptors and is a multi-pass membrane protein that localizes to the plasma membrane. The protein binds estradiol, resulting in intracellular calcium mobilization and synthesis of phosphatidylinositol (3,4,5)-trisphosphate in the nucleus.[9] This protein therefore plays a role in the rapid nongenomic signaling events widely observed following stimulation of cells and tissues with estradiol.[21] The distribution of GPER is well established in the rodent, with high expression observed in the hypothalamus, pituitary gland, adrenal medulla, kidney medulla and developing follicles of the ovary.[22]

Role in cancer

[edit]

GPER expression has been studied in cancer using immunohistochemical and transcriptomic approaches, and has been detected in: colon, lung, melanoma, pancreatic, breast,[23] ovarian,[24] and testicular cancer.[25]

Many groups have demonstrated that GPER signaling is tumor suppressive in cancers that are not traditionally hormone responsive, including melanoma, pancreatic, lung and colon cancer.[26][27][28][29] Additionally, many groups have demonstrated that GPER activation is also tumor suppressive in cancers that are classically considered sex hormone responsive, including endometrial cancer, ovarian cancer, prostate cancer, and Leydig cell tumors.[30][31][32][33][34] Although GPER signaling was originally thought to be tumor promoting in some breast cancer models,[35] subsequent reports show that GPER signaling inhibits breast cancer.[36][37][38] Consistent with this, recent studies showed that the presence of GPER protein in human breast cancer tissue correlates with longer survival.[39] In summary, many independent groups have demonstrated that GPER activation may be a therapeutically useful mechanism for a wide range of cancer types.

Linnaeus Therapeutics is currently running NCI clinical trial (NCT04130516) using GPER agonist, LNS8801, as monotherapy and in combination with the immune checkpoint inhibitor, pembrolizumab, for the treatment of multiple solid tumor malignancies. Activation of GPER with LNS8801 has demonstrated efficacy in humans in cutaneous melanoma, uveal melanoma, lung cancer, neuroendocrine cancer, colorectal cancer, and other PD-1 inhibitor refractory cancers.[40][41][42]

Role in normal tissues

[edit]

Reproductive tissue

[edit]

Estradiol produces cell proliferation in both normal and malignant breast epithelial tissue.[43][44] However, GPER knockout mice show no overt mammary phenotype, unlike ERα knockout mice, but similarly to ERβ knockout mice.[43] This indicates that although GPER and ERβ play a modulatory role in breast development, ERα is the main receptor responsible for estrogen-mediated breast tissue growth.[43] GPER is expressed in germ cells and has been found to be essential for male fertility, specifically, in spermatogenesis.[45][46][47][48] GPER has been found to modulate gonadotropin-releasing hormone (GnRH) secretion in the hypothalamic-pituitary-gonadal (HPG) axis.[48]

Cardiovascular effects

[edit]

GPER is expressed in the blood vessel endothelium and is responsible for vasodilation and as a result, blood pressure lowering effects of estradiol.[49] GPER also regulates components of the renin–angiotensin system, which also controls blood pressure,[50][51] and is required for superoxide-mediated cardiovascular function and aging.[52]

Central nervous system activity

[edit]

GPER and ERα, but not ERβ, have been found to mediate the antidepressant-like effects of estradiol.[53][54][55] Contrarily, activation of GPER has been found to be anxiogenic in mice, while activation of ERβ has been found to be anxiolytic.[56] There is a high expression of GPER, as well as ERβ, in oxytocin neurons in various parts of the hypothalamus, including the paraventricular nucleus and the supraoptic nucleus.[55][57] It is speculated that activation of GPER may be the mechanism by which estradiol mediates rapid effects on the oxytocin system,[55][57] for instance, rapidly increasing oxytocin receptor expression.[58] Estradiol has also been found to increase oxytocin levels and release in the medial preoptic area and medial basal hypothalamus, actions that may be mediated by activation of GPER and/or ERβ.[58] Estradiol, as well as tamoxifen and fulvestrant, have been found to rapidly induce lordosis through activation of GPER in the arcuate nucleus of the hypothalamus of female rats.[59][60]

Metabolic roles

[edit]

Female GPER knockout mice display hyperglycemia and impaired glucose tolerance, reduced body growth, and increased blood pressure.[61] Male GPER knockout mice are observed to have increased growth, body fat, insulin resistance and glucose intolerance, dyslipidemia, increased osteoblast function (mineralization), resulting in higher bone mineral density and trabecular bone volume, and persistent growth plate activity resulting in longer bones.[62][63] The GPER-selective agonist G-1 shows therapeutic efficacy in mouse models of obesity and diabetes.[64]

Role in neurological disorders

[edit]

GPER is broadly expressed on the nervous system, and GPER activation promotes beneficial effects in several brain disorders.[65] A study suggests that GPER levels were significantly lower in children with ADHD compared to controls.[66]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

GPER

View on Grokipedia
from Grokipedia
The G protein-coupled estrogen receptor (GPER), also known as GPR30 or GPER1, is a seven-transmembrane domain receptor belonging to the class A family of G protein-coupled receptors (GPCRs) that mediates rapid, non-genomic estrogen signaling distinct from the classical nuclear estrogen receptors ERα and ERβ. Encoded by the GPER1 gene on human chromosome 7p22.3, GPER consists of 375 amino acids and is widely expressed in tissues including the brain, heart, lungs, liver, reproductive organs, and immune cells. It binds 17β-estradiol with high affinity (pKi 8.2–8.5) and activates intracellular pathways such as adenylyl cyclase via Gs proteins and phospholipase C via Gi/o proteins, leading to rapid cellular responses like increased cAMP, calcium mobilization, and ERK phosphorylation. First identified in the mid-1990s through cloning from cell lines and later confirmed as an in 2000–2005, GPER has been recognized for its evolutionary conservation spanning over 450 million years, highlighting its fundamental role in . Structurally, GPER localizes to the plasma membrane and , where it facilitates both membrane-initiated signaling and potential interactions with nuclear transcription factors, contributing to both short-term and longer-term effects. Selective agonists like G-1 and antagonists such as G15 and G36 have been developed to probe its pharmacology, revealing its responsiveness to both endogenous estrogens and environmental estrogenic compounds. In physiological contexts, GPER regulates diverse processes including reproductive functions (e.g., follicular development and ), cardiovascular protection (e.g., and reduced ), immune modulation (e.g., effects), and metabolic (e.g., insulin sensitivity). It also influences neurological functions such as against ischemia and age-related cognitive decline. In disease, GPER is implicated in hormone-sensitive cancers like , endometrial, and ovarian tumors, where it can promote proliferation and resistance to therapies such as , though its role varies by context (pro-tumorigenic or protective). Additionally, it contributes to cardiovascular pathologies including and metabolic disorders like and , positioning GPER as a promising therapeutic target with ongoing clinical trials evaluating selective modulators for conditions such as and postmenopausal cardiovascular risk.

Discovery and Nomenclature

Initial Identification

The G protein-coupled estrogen receptor (GPER), initially designated as GPR30, was first cloned in 1996 by Owman et al. from human B-cell lymphoblasts using PCR with degenerate primers targeting G protein-coupled receptor (GPCR) sequences. This effort yielded a full-length cDNA encoding a 375-amino acid protein with seven transmembrane domains, characteristic of the GPCR superfamily, expressed in Burkitt's lymphoma cell lines and various tissues including brain, heart, lung, and kidney. At the time, it was classified as an orphan receptor with no known ligand or function. In 1997, Carmeci et al. independently cloned GPR30 from a breast cancer cDNA library through differential screening, identifying high expression in estrogen receptor (ER)-positive breast carcinoma cell lines and tissues, as well as in the ER-negative SKBR3 breast cancer cell line. Sequence analysis confirmed its identity as the same orphan GPCR, with homology to chemokine receptors but distinct features, suggesting a potential role in hormonally responsive cancers. This work established GPR30's association with breast cancer cells, prompting further investigation into its physiological relevance. Early functional characterization in the revealed GPR30's responsiveness to and its distinction from classical nuclear ERα and ERβ. Filardo et al. (2000) demonstrated that GPR30 expression correlates with rapid -induced activation of (MAPK) in cells, with antisense knockdown abolishing this non-genomic signaling. Subsequent studies showed direct binding to GPR30, as of the receptor into ER-negative HEK293 cells triggered rapid intracellular calcium and phosphatidylinositol 3,4,5-trisphosphate accumulation within seconds of exposure, effects absent in untransfected cells and independent of ERα/ERβ. In ER-negative SKBR3 cells, GPR30 mediated -stimulated c-fos proto-oncogene expression via an EGFR/MAPK pathway, further highlighting its role in rapid, membrane-initiated signaling. These findings positioned GPR30 as a , later officially renamed GPER. In , the International Union of Basic and (IUPHAR) officially renamed GPR30 as GPER (G protein-coupled ) to reflect its established function as an .

Evolution of Understanding

Following its initial cloning in 1996 as an , research on GPR30 (now known as GPER) progressed to establish its identity as a bona fide through key studies in the mid-2000s. In 2005, Thomas et al. demonstrated that GPER exhibits high-affinity binding to 17β-estradiol with a (Kd) of approximately 3 nM in human cell membranes, confirming specific estrogen interaction independent of classical nuclear receptors (ERα and ERβ). This was complemented by showing GPER localization to the plasma membrane in transfected cells. In 2007, Prossnitz et al. further validated these findings using a fluorescent estradiol derivative, reporting a Kd of about 4 nM and visualizing membrane-associated binding via , thus solidifying GPER's role in rapid signaling. These discoveries sparked debates over whether GPER functions as a true or merely as a co-receptor facilitating classical ER signaling. Early arose from observations in ER-positive cells where GPER effects overlapped with ERα/ERβ pathways, but subsequent evidence from ER-negative cell lines, such as SKBR-3 cells lacking functional classical ERs, showed GPER-mediated calcium mobilization and ERK activation in response to , independent of nuclear ERs. Knockdown experiments using GPER-specific siRNA in these cells abolished responses, while ERα/β antagonists had no effect, resolving the debate by demonstrating GPER's autonomous signaling capacity. The development of selective ligands played a crucial role in validating GPER's specificity. In 2006, Bologa et al. identified G-1, the first non-steroidal selective for GPER (with micromolar potency and no binding to ERα/ERβ), which elicited rapid signaling events like IP3 production and c-fos induction in GPER-expressing cells, confirming its functional distinction from classical receptors. During the , structural insights advanced through computational methods, as no experimental was available. Homology models based on related GPCRs, such as β2-adrenergic receptor templates, predicted GPER's seven-transmembrane helical bundle and identified key residues in the ligand-binding pocket, enabling for novel modulators and refining understanding of docking. These models highlighted conserved motifs in transmembrane domains III and VI critical for GPER activation, facilitating predictions of ligand specificity. In the 2020s, research has deepened appreciation of GPER's involvement in non-genomic signaling, particularly its interaction with aldosterone as a secondary . Studies confirmed aldosterone binds GPER with nanomolar affinity, triggering EGFR and vascular effects independent of receptors, as shown in radioligand binding assays and functional assays in endothelial cells. This has implications for cardiovascular regulation, with GPER knockout models exhibiting altered aldosterone responses, underscoring its role in rapid, membrane-initiated pathways beyond estrogens.

Molecular Structure and Expression

Protein Structure

GPER is a 375-amino acid protein encoded by the GPER1 gene located on human 7p22.3. As a member of the class A (GPCR) family, it exhibits the canonical architecture of seven transmembrane α-helices arranged in a bundle, connected by three intracellular and three extracellular loops, with an extracellular N-terminal domain and an intracellular C-terminal tail. Characteristic structural motifs of GPCRs are present in GPER, including the conserved DRY box (Asp-Arg-Tyr) at the cytoplasmic end of TM3, which plays a critical role in stabilizing the inactive state and facilitating coupling upon activation. Recent cryo-EM structures from 2024 have provided high-resolution insights into GPER's active conformation, revealing a negatively charged orthosteric ligand-binding pocket formed by residues primarily from TM3, TM6, and TM7, along with contributions from extracellular loop 2 (ECL2). These structures, including complexes with and ligands such as Lys05, indicate that the pocket does not accommodate direct binding of (E2), challenging prior models of interaction and suggesting alternative endogenous ligands like . Post-translational modifications significantly influence GPER's localization and function. N-linked occurs at three residues (Asn25, Asn32, and Asn44) in the extracellular N-terminal domain, which is essential for proper receptor folding, trafficking from the to the plasma , and overall maturation. Palmitoylation at a C-terminal residue enhances membrane anchoring and stability, a common feature among GPCRs that regulates signaling efficiency. GPER displays to other class A GPCRs, such as the II type 1 receptor, with shared transmembrane topology but distinct ligand-binding determinants; recent structures indicate the pocket does not support direct binding.

Gene and Tissue Distribution

The , located on human chromosome 7p22.3, consists of three exons spanning approximately 12 kb. Its promoter region contains binding sites for Sp1 and Sp3 transcription factors, which mediate responsiveness through interactions with , facilitating transcriptional activation. GPER1 exhibits a broad but heterogeneous expression profile across human tissues, with high levels detected in the breast, ovary, uterus, heart, brain, and vascular endothelium based on RNA-seq and immunohistochemistry data. In contrast, expression is notably low in the liver and skeletal muscle, as evidenced by quantitative transcriptomic analyses. These patterns reflect GPER1's role in estrogen-sensitive systems, with data from large-scale RNA-seq consortia confirming consistent tissue-specific distribution up to 2025. Expression of GPER1 is upregulated by in cancer cells, particularly in and endometrial lines, where it acts as a transcriptional target of the estrogen-ERα signaling axis. In aging tissues, GPER1 levels decline in certain contexts, such as the and vasculature, potentially influenced by age-related epigenetic changes, though specific miRNA mechanisms like miR-148a primarily link to estrogen-mediated downregulation rather than direct suppression of GPER1. GPER1 is highly conserved across mammals, with orthologs present in species such as the (Gper1 on ), where the protein shares approximately 83% sequence identity with the human counterpart. This conservation extends to other mammals like and non-human , maintaining 85-95% identity in key functional domains. While primarily localized to the plasma membrane as a seven-transmembrane receptor, GPER1 also appears in intracellular compartments, including endocytic vesicles and the nucleus, depending on cellular context and stimulation. This dynamic distribution supports both rapid membrane signaling and potential nuclear effects.

Ligands and Pharmacology

Endogenous Activators

The primary endogenous activator of the G protein-coupled receptor (GPER) is 17β-estradiol (E2), which binds with high affinity, typically exhibiting a (Kd) or half-maximal effective concentration () in the range of 3-6 nM. This interaction enables E2 to mediate rapid, non-genomic signaling events through GPER, distinct from classical nuclear s. Binding of E2 to GPER has been confirmed across various cell types, including those expressing recombinant human GPER, where it displaces radiolabeled ligands with high specificity. Other endogenous estrogens, such as () and estrone (E1), interact with GPER with lower affinity compared to E2. acts as an at micromolar concentrations, while estrone exhibits even lower affinity, with binding constants exceeding 10 μM. These weaker interactions suggest a supplementary role for and E1 in GPER modulation under physiological conditions where E2 levels may fluctuate, such as during or postmenopause. Among non-estrogen endogenous ligands, aldosterone binds to GPER with moderate affinity, Ki ≈ 24 nM (95% CI: 4.1–100 nM), and activates similar rapid signaling pathways, potentially contributing to transport regulation in responsive tissues. This binding has been demonstrated through competitive displacement assays using radiolabeled E2, highlighting aldosterone's role as a functional in contexts like cardiovascular and . An endogenous of GPER is CCL18, which competitively inhibits GPER . No other firmly established endogenous antagonists of GPER have been identified; however, progesterone and its metabolites exhibit very low binding affinity. The binding kinetics of endogenous activators to GPER are characterized by rapid association and dissociation rates, often completing within a few minutes, which facilitates non-genomic actions occurring on timescales of seconds to minutes. This dynamic profile, observed in radioligand binding studies with E2, underscores GPER's suitability for mediating acute physiological responses rather than sustained transcriptional changes.

Synthetic Agonists and Antagonists

Synthetic agonists of the G protein-coupled receptor (GPER) have been developed to selectively activate this receptor without significant interaction with classical receptors (ERα and ERβ). The first selective GPER agonist, G-1, was identified in 2006 through virtual and biomolecular screening; it exhibits high affinity for GPER with a Ki of 11 nM and an of approximately 2 nM for GPER-mediated calcium mobilization, while showing no binding or functional activity at ERα or ERβ at concentrations up to 10 μM. Other compounds, such as the ERα-selective agonist PPT and the ERβ-selective agonist DPN, function as partial agonists at GPER despite their primary selectivity for classical ERs, with PPT demonstrating GPER activation at concentrations around 10 nM in certain cellular assays. Non-steroidal antagonists like G-15 and G-36 competitively bind to the GPER pocket, blocking - or G-1-induced signaling such as calcium release and PI3K activation. G-15, developed in 2009, is a high-affinity GPER with a Ki of 20 nM and over 1,000-fold selectivity against ERα and ERβ, effectively inhibiting GPER-mediated responses and . G-36, an improved analog, displays values of 112 nM against 17β-estradiol-induced calcium mobilization and 165 nM against G-1-induced responses, with reduced to ERα compared to G-15. Developing highly selective GPER modulators remains challenging due to structural similarities in ligand-binding domains between GPER and classical ERs, leading to frequent ; for instance, early antagonists like G-15 showed low-affinity binding to ERα, necessitating refinements like G-36 for enhanced specificity. Recent advancements in the 2020s include enantiomerically pure agonists such as LNS8801, which maintains potent GPER selectivity and demonstrates oral in preclinical models. Pharmacokinetic profiles of these compounds vary; G-1 exhibits a short plasma half-life and limited oral bioavailability, restricting its use primarily to injectable or in vitro applications, though it has been employed effectively in mouse models of disease. In contrast, G-15 has been successfully administered in vivo to inhibit tumor growth in estrogen-sensitive models without notable bioavailability issues. Therapeutically, GPER agonists like G-1 show promise for , reducing neuronal injury and in models of cerebral ischemia and through mechanisms independent of classical ERs. Antagonists such as G-15 and G-36 hold potential for treating estrogen-sensitive tumors, including non-small cell and endometrial , by blocking GPER-mediated proliferation; preclinical data support their use, with phase 2/3 clinical trials of GPER agonists like LNS8801 ongoing as of 2025 for advanced solid malignancies, including .

Signaling Mechanisms

G Protein Interactions

Upon ligand binding, GPER couples to multiple heterotrimeric G protein subtypes, including Gαs, Gαi/o, and , with coupling varying by ligand and cellular context. Traditionally, activation by was thought to primarily involve Gαs and Gαi/o, modulating activity. Coupling to Gαs stimulates , resulting in increased intracellular cAMP levels, as demonstrated in early studies using ER-negative cells where promoted cAMP production via GPR30 (now known as GPER). In contrast, coupling to Gαi/o inhibits , leading to decreased cAMP, with this pathway showing sensitivity to , which ADP-ribosylates and uncouples Gαi/o from the receptor. However, a 2024 study identified bicarbonate as a physiological ligand that activates GPER via Gq coupling, leading to phospholipase C activation and calcium mobilization, without evidence of estrogen activation in vitro. This finding has sparked debate on GPER's role as an estrogen receptor, with some evidence suggesting bicarbonate may be the primary endogenous activator. Activation of GPER also promotes the dissociation of the into Gα and Gβγ subunits, with the released Gβγ dimers playing a critical role in downstream signaling by directly activating (PI3K) and Src kinase. This Gβγ-mediated activation occurs independently of Gαs but is pertussis toxin-sensitive when involving Gαi/o, highlighting the subunit's importance in rapid non-genomic effects. Ligand-induced conformational changes in GPER facilitate G protein coupling, particularly through outward movement of transmembrane helix 6 (TM6) at its intracellular end, which disrupts the inactive-state ionic lock and exposes the DRY motif in TM3 for interaction with the Gα C-terminus. Homology models based on crystal structures of other GPCRs show this TM6 displacement (approximately 4.3 Å RMSD from inactive state). Recent cryo-EM structures of agonist-bound GPER-Gq complexes confirm similar activation mechanisms, including TM6 outward movement and bicarbonate binding sites. Evidence for these interactions includes functional assays showing pertussis toxin inhibition of Gαi/o-dependent signaling, such as Src and EGFR transactivation, and bioluminescence resonance energy transfer (BRET) studies demonstrating GPER's proximity to Gαs in cellular complexes, where increasing GPER expression perturbs Gαs to other receptors. GPER exhibits to Gαs, Gαi/o, and in a context- and ligand-dependent manner, influencing signaling bias; for instance, Gαs predominates in some cells to drive cAMP elevation and proliferation, while Gαi/o is prominent in neuronal contexts to modulate inhibitory pathways, and Gq mediates calcium responses to . This versatility allows GPER to elicit diverse physiological responses without detailed elaboration on downstream kinases.

Intracellular Pathways

Upon by , synthetic agonists, or , GPER initiates several rapid intracellular signaling cascades primarily through subunits, particularly Gβγ, independent of classical nuclear pathways. These non-genomic signals occur within seconds to minutes and modulate diverse cellular processes such as proliferation, , and migration. However, the direct by remains controversial, with recent supporting as a key activator. A prominent pathway is the (MAPK)/extracellular signal-regulated kinase (ERK) cascade, activated via a Gβγ-dependent mechanism involving Src , the adaptor protein Shc, and Ras. This leads to rapid of ERK1/2, typically within 5-15 minutes, promoting downstream effects like through transcription factors such as Elk1. In various cell types, including cells, this pathway is pertussis toxin-sensitive, indicating G_i/o involvement, and contributes to or, contextually, via p21 upregulation. GPER also stimulates the (PI3K)/Akt pathway through Gβγ subunits, enhancing cell survival and migration. This activation is evident in endothelial cells, where it promotes endothelial nitric oxide synthase (eNOS) phosphorylation, production, and . Inhibitors like LY294002 block this pathway, distinguishing it from classical ERα signaling, and it plays a key role in cardioprotective effects. Calcium mobilization is another critical response, mediated by (PLC) activation, which generates (IP3) to release Ca²⁺ from stores. This process, now linked to coupling with , is independent of voltage-gated calcium channels and occurs rapidly in cells like vascular and renal tubules, activating (PKC) and influencing contractility or secretion. In GPER knockout models, ligand-induced calcium fluxes are absent, confirming receptor specificity. Additional pathways include (EGFR) transactivation, where GPER signals via Src to stimulate matrix metalloproteinases (MMPs) that shed heparin-bound EGF (HB-EGF), leading to EGFR dimerization and downstream MAPK or PI3K activation. In G_s-coupled contexts, GPER elevates via , activating (PKA) and phosphorylating targets like CREB for gene regulation. GPER exhibits cross-talk with classical estrogen receptors (ERα/ERβ) through Src-mediated mechanisms, amplifying non-genomic effects and modulating ER transcriptional activity, though GPER itself does not directly bind DNA.

Physiological Roles

Reproductive Functions

GPER mediates rapid, non-genomic signaling in the , playing a key role in follicular development and through activation of the ERK pathway. In human granulosa cells, GPER forms heteromeric complexes with the (FSHR), which reprograms FSH signaling to promote cell proliferation and survival via ERK1/2 and PI3K/AKT pathways, thereby supporting dominant follicle selection and maturation during follicular growth. Similarly, in ovaries, binding to GPER on membranes rapidly elevates cAMP and activates ERK1/2 via EGFR transactivation, inhibiting premature maturation and maintaining meiotic arrest until the trigger. In the , GPER facilitates non-genomic effects that enhance endometrial function, including and essential for reproductive preparedness. Activation of GPER by or the selective G-1 induces rapid in uterine arteries through endothelial activation and smooth muscle cAMP elevation, improving blood flow to support endometrial growth. GPER also stimulates proliferation of endometrial epithelial cells, with G-1 treatment eliciting approximately threefold increases in cell numbers in ovariectomized models, contributing to uterine remodeling during the . Studies indicate GPER supports uterine receptivity for implantation, as its activation modulates endometrial and stromal preparation, though global GPER mice exhibit largely intact with potential subtle deficits in implantation efficiency under stress conditions. GPER is expressed in the mammary epithelium and regulates ductal growth and through rapid signaling. In tissue, GPER mediates non-genomic effects that promote ductal elongation and branching during pubertal development, as evidenced by enhanced proliferation in GPER-expressing epithelial cells exposed to . During , GPER supports alveolar function and production by facilitating rapid calcium and cAMP signaling in epithelial cells, maintaining secretory activity in response to hormonal cues. In male reproduction, GPER enhances and function via non-genomic . In spermatozoa, GPER activation by triggers intracellular calcium mobilization through PLC-dependent pathways and CatSper channel-mediated influx, increasing progressive motility and promoting the necessary for fertilization. Additionally, GPER contributes to relaxation, where agonist stimulation reduces contractility via cAMP elevation, aiding seminal fluid expulsion during . GPER modulates the by contributing to the timing of the (LH) surge through hypothalamic crosstalk, emphasizing its non-genomic role in central reproductive regulation. Rapid GPER signaling in hypothalamic neurons enhances excitability and GnRH release in response to rising levels, synchronizing the preovulatory LH surge and maintaining cycle rhythmicity. This central action ties into broader neurological effects on , where GPER influences neuroendocrine circuits beyond peripheral gonadal functions.

Cardiovascular Regulation

GPER, also known as GPR30, plays a significant role in maintaining cardiovascular through its expression in , vascular cells (VSMCs), and cardiomyocytes. Activation of GPER by (E2) or selective agonists like G-1 promotes rapid, non-genomic signaling that modulates vascular tone and cardiac function. High levels of GPER are found in the endothelium of , where it facilitates (NO) production, mimicking the vasodilatory effects of E2. A primary mechanism of GPER-mediated cardiovascular is , achieved through activation of endothelial (eNOS) via the PI3K/Akt pathway, which enhances NO and reduces , particularly in females. This process involves rapid of eNOS, leading to endothelium-dependent relaxation in arteries such as mesenteric and coronary vessels. Studies in ovariectomized models demonstrate that G-1 administration lowers systolic by suppressing the renin-angiotensin system and promoting NO-mediated . Sex differences are evident, with GPER effects more pronounced in females due to higher endothelial expression and pathway preferences, such as MEK-ERK-eNOS signaling, contributing to better in premenopausal women. GPER also exerts anti-atherosclerotic effects by inhibiting VSMC proliferation and migration, thereby preventing vascular remodeling and plaque formation. In apoE-/- mouse models, GPER reduces endothelial apoptosis, lowers plasma lipids, and attenuates progression, highlighting its role against inflammatory vascular damage. Furthermore, GPER contributes to cardiac , particularly in preconditioning against ischemia-, through of the ERK1/2 and reperfusion injury salvage kinase () pathways, which mitigate mitochondrial dysfunction and improve myocardial recovery. These cardioprotective actions are more robust in females, underscoring GPER's involvement in sex-specific cardiovascular resilience.

Neurological and Metabolic Effects

G protein-coupled estrogen receptor (GPER), also known as GPR30, mediates neuroprotective effects in the (CNS) primarily through rapid non-genomic signaling pathways. Activation of GPER by the selective G-1 promotes the expression and release of (BDNF), which supports neuronal survival and in models of cerebral ischemia. In models, GPER stimulation enhances anti-apoptotic mechanisms by increasing levels and reducing pro-apoptotic factors such as BAX and cleaved caspase-3, thereby attenuating neuronal and infarct size following ischemic injury. These effects are particularly evident in ovariectomized , where GPER agonism mimics estrogen's protective role against acute brain damage. GPER also contributes to mood regulation, exerting anxiolytic effects that alleviate anxiety-like behaviors. The agonist G-1 reduces anxiety in open-field and elevated plus-maze tests by modulating GABAergic and glutamatergic transmission balance in the basolateral amygdala, independent of classical estrogen receptors. In ovariectomized models of menopausal depression, GPER activation via G-1 enhances translocator protein (TSPO) phosphorylation through protein kinase A (PKA) signaling, leading to antidepressant and anxiolytic outcomes that counteract inflammation and stress responses. In metabolic regulation, GPER influences insulin sensitivity in adipocytes by activating the PI3K/AKT pathway, which enhances glucose uptake and mitigates insulin resistance under high-fat diet conditions. Genetic deficiency of GPER in mice results in increased adiposity, impaired glucose tolerance, and obesity, particularly in males, highlighting its role in maintaining energy homeostasis. Liver expression of GPER modulates gluconeogenesis by suppressing hepatic glucose production and promoting glycogen synthesis, thereby contributing to overall glucose homeostasis. Recent studies link GPER agonism to potential therapeutic benefits in type 2 diabetes, with 2025 research demonstrating that GPER signaling preserves pancreatic β-cell identity and insulin secretion, countering menopausal estrogen decline that exacerbates hyperglycemia. In adipose tissue, GPER promotes lipolysis through PKA-dependent phosphorylation of hormone-sensitive lipase, facilitating fat mobilization in postmenopausal models. It also exhibits sex-specific effects post-menopause, enhancing insulin sensitivity and reducing visceral fat accumulation in females via targeted activation in metabolic tissues. GPER influences metabolism by regulating hypothalamic appetite control, where its deficiency impairs cholecystokinin-mediated signaling, leading to increased intake. Although direct links to circadian rhythms remain under investigation, GPER's expression in hypothalamic nuclei suggests a role in coordinating energy balance with daily metabolic cycles.

Pathological Implications

Involvement in Cancer

GPER, also known as GPR30, has been implicated in the progression of various hormone-related cancers, with its overexpression frequently associated with adverse outcomes. In , elevated GPER expression correlates with poor prognosis, larger tumor size, and increased risk, particularly in estrogen receptor-positive subtypes where it contributes to endocrine resistance. GPER activation promotes and through EGFR transactivation, enhancing epithelial-to-mesenchymal transition (EMT) and tumor dissemination. In (TNBC), high GPER levels are linked to worse relapse-free survival and lymph node , underscoring its role in aggressive disease phenotypes. Beyond , GPER influences tumorigenesis in endometrial, ovarian, and cancers. In endometrial and ovarian cancers, GPER overexpression predicts poor and correlates with progression, where it facilitates proliferation in ER-negative cell lines via non-genomic signaling pathways. In , GPER expression exhibits a dual influence, with certain polymorphisms associated with increased risk and others potentially protective, though its activation generally supports cell motility and androgen-independent growth. Mechanistically, GPER drives these effects through rapid non-genomic pathways that induce EMT, via VEGF upregulation, and cross-talk with HER2, amplifying oncogenic signaling in the . Therapeutic targeting of GPER holds promise for mitigating cancer progression, particularly with selective antagonists. The GPER antagonist G-15 has demonstrated efficacy in preclinical models, reducing tumor growth in breast cancer xenografts by inhibiting proliferation and migration, and reversing resistance to standard therapies. In TNBC xenografts, GPER knockdown similarly suppresses tumor expansion, highlighting its potential as a target for aggressive subtypes. As of 2025, clinical trials for GPER agonists like LNS8801 (NCT04130516) are underway in various advanced solid tumors, such as melanoma, to explore anti-proliferative effects; as of November 2025, phase 1/2 trials continue, demonstrating safety and preliminary efficacy in immunotherapy-refractory melanoma when combined with pembrolizumab. Inhibitor-based therapies remain in preclinical stages, with ongoing research evaluating G-15 analogs for TNBC. The role of GPER in cancer remains controversial due to its context-dependent effects, acting as pro-tumorigenic in many hormone-driven malignancies while exhibiting anti-tumor properties in others through induction of and arrest. For instance, GPER activation can promote in cells but enhance survival in stem cells, complicating therapeutic strategies and necessitating tumor-specific approaches.

Roles in Metabolic and Neurological Disorders

GPER signaling contributes to the aggravation of in , as evidenced by studies showing that GPER knockout mice are protected from high-fat diet-induced , glucose intolerance, and compared to wild-type counterparts. In contrast, activation of GPER with selective agonists such as G-1 enhances in adipocytes and , thereby improving metabolic efficiency and counteracting . Recent analyses, including bioinformatics studies of human data from postmenopausal women, have provided insights into GPER's role in metabolic regulation, supporting preclinical observations of improved insulin sensitivity. In the context of diabetes, GPER exerts protective effects on pancreatic β-cells by facilitating insulin and shielding cells from -induced damage. GPER models display exacerbated and diminished β-cell mass, underscoring the receptor's essential role in preserving insulin-producing capacity and preventing disease progression. These findings suggest that GPER agonism could serve as a therapeutic strategy to bolster β-cell function in . GPER also plays neuroprotective roles in neurodegenerative disorders. In , higher GPER expression attenuates the pathological interplay between amyloid-β plaques and tau tangles, potentially via ERK signaling pathways that reduce amyloid-β accumulation and promote neuronal survival. Similarly, in , GPER activation with the agonist G-1 confers dopaminergic by suppressing microglial activation and neuroinflammation in toxin-induced models, thereby preserving striatal levels and motor function. For , GPER agonism with G-1 ameliorates disease severity in experimental autoimmune encephalomyelitis models through anti-inflammatory modulation of T-cells, including enhanced regulatory T-cell differentiation and inhibition of pro-inflammatory Th17 responses. Therapeutically, the GPER G-1 accelerates by restoring cerebral microvascular endothelial function and reducing ischemia-reperfusion injury in preclinical models. In obesity-related , GPER antagonists like G-36 offer potential by inhibiting receptor-driven , as blocking GPER signaling mitigates polarization toward pro-inflammatory states.

References

  1. https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=221
  2. https://www.nature.com/articles/s41574-023-00822-7
  3. https://www.annualreviews.org/doi/10.1146/annurev-pharmtox-031122-121944
  4. https://doi.org/10.1006/bbrc.1996.1654
  5. https://doi.org/10.1006/geno.1997.4972
  6. https://www.sciencedirect.com/science/article/abs/pii/S0960076017300869
  7. https://pubmed.ncbi.nlm.nih.gov/15539556/
  8. https://pubmed.ncbi.nlm.nih.gov/17222505/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC2740807/
  10. https://pubmed.ncbi.nlm.nih.gov/16520733/
  11. https://pubmed.ncbi.nlm.nih.gov/33164654/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7417359/
  13. https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.995
  14. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1226458/full
  15. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1513225/full
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC5716468/
  17. https://pubmed.ncbi.nlm.nih.gov/38744981/
  18. https://elifesciences.org/reviewed-preprints/99874
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC6390128/
  20. https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2022.843502/full
  21. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.00148/full
  22. https://www.ncbi.nlm.nih.gov/gene/2852
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC8741193/
  24. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.00390/full
  25. https://academic.oup.com/endo/article/150/4/1722/2455712
  26. https://www.proteinatlas.org/ENSG00000164850-GPER1
  27. https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1097018/full
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC4421993/
  29. https://www.informatics.jax.org/marker/MGI:1924104
  30. https://rddc.tsinghua-gd.org/gene/76854
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC9533654/
  32. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1338448/full
  33. https://portlandpress.com/bioscirep/article/39/2/BSR20182436/110939/Human-G-protein-coupled-receptor-30-is-N
  34. https://www.sciencedirect.com/science/article/abs/pii/S0960076024000712
  35. https://academic.oup.com/endo/article/153/7/2953/2423548
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC10153636/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC4040308/
  38. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00725/full
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC9446082/
  40. https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.2019.33.1_supplement.503.9
  41. https://www.intechopen.com/chapters/82778
  42. https://pubmed.ncbi.nlm.nih.gov/19430488/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC3220788/
  44. https://www.sciencedirect.com/science/article/abs/pii/S0960076011001476
  45. https://aacrjournals.org/cancerrescommun/article/5/4/556/754636/LNS8801-An-Enantiomerically-Pure-Agonist-of-the-G
  46. https://www.science.org/doi/10.1126/scitranslmed.aau5956
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC7848463/
  48. https://www.ahajournals.org/doi/10.1161/strokeaha.112.678177
  49. https://clinicaltrials.gov/study/NCT06624644
  50. https://doi.org/10.1210/mend.16.1.0758
  51. https://doi.org/10.1210/mend.14.10.0532
  52. https://www.nature.com/articles/s41467-024-45579-3
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC3144530/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC4517684/
  55. https://www.rcsb.org/structure/8XOJ
  56. https://doi.org/10.1074/jbc.M411659200
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC10187525/
  58. https://doi.org/10.1016/j.isci.2020.101812
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC2874603/
  60. https://doi.org/10.1093/molehr/gat095
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC3474542/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC4733493/
  63. https://journals.physiology.org/doi/full/10.1152/physiolgenomics.00105.2017
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC9467539/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC11444091/
  66. https://doi.org/10.3390/biom13091410
  67. https://doi.org/10.1152/ajprenal.00045.2020
  68. https://doi.org/10.1016/j.lfs.2017.06.020
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC6425826/
  70. https://pubmed.ncbi.nlm.nih.gov/23669322/
  71. https://pubmed.ncbi.nlm.nih.gov/33345973/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC12382220/
  73. https://academic.oup.com/endo/article/154/11/4136/2422809
  74. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-07005-0
  75. https://www.researchgate.net/publication/391779484_G_Protein_Coupled_Estrogen_Receptor_Signaling_Maintains_b_Cell_Identity_in_Female_Mice
  76. https://pubmed.ncbi.nlm.nih.gov/38201867/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC4568147/
  78. https://jeccr.biomedcentral.com/articles/10.1186/s13046-024-03096-7
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC9427744/
  80. https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0579-y
  81. https://ec.bioscientifica.com/view/journals/ec/8/6/EC-19-0164.xml
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC3863501/
  83. https://onlinelibrary.wiley.com/doi/10.1111/andr.12131
  84. https://www.mdpi.com/2073-4409/12/20/2460
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC7468389/
  86. https://www.mdpi.com/1422-0067/20/2/306
  87. https://www.nature.com/articles/s41420-023-01654-0
  88. https://clinicaltrials.gov/study/NCT04130516
  89. https://www.annalsofoncology.org/article/S0923-7534(24)03659-7/fulltext
  90. https://www.dovepress.com/double-edged-role-of-g-protein-coupled-estrogen-receptor-1-in-breast-c-peer-reviewed-fulltext-article-OTT
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC11475807/
  92. https://www.mdpi.com/2072-6694/17/16/2623
  93. https://www.nature.com/articles/srep34302
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC11567725/
  95. https://academic.oup.com/endo/article/152/8/3030/2457223
  96. https://www.nature.com/articles/s42003-024-06272-9
  97. https://pubmed.ncbi.nlm.nih.gov/28810246/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC3635139/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC3923380/
  100. https://www.mdpi.com/1422-0067/25/17/9532
Add your contribution
Related Hubs
User Avatar
No comments yet.